Authors


Kenton H. Steele, Esq

Latest:

How an opening statement can make or break a malpractice case

"An attorney who just reads off a script spewing random facts at the jury will likely cause the jurors to check out," writes Kenton H. Steele, Esq.


Christopher B. Anderson MD, MPH

Latest:

Management of hormone-naïve oligometastatic prostate cancer

Growing evidence supports the existence of an intermediate metastatic disease state.


Jenna K. Horton, NP

Latest:

Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

Experts outline their clinical approach to identifying treatment failure in patients on initial pharmacologic treatment for OAB and strategies for subsequent treatment selection.


Stephen J. Freedland, MD

Latest:

Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.


Juan Montoya, MD

Latest:

Insights on Perirectal Spacing in Prostate Cancer

In the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.


Michael Gorin, MD

Latest:

The Future of Prostate Cancer Imaging

Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.


Nicholas W. Eyrich, MS

Latest:

Integrating video visits into urologic training

"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.


Karim Chamie, MD

Latest:

Clinical Pearls for Community Urologists Treating Patients with MIBC

Dr Chamie shares advice for community urologists treating patients with MIBC.


Media Department, US Urology Partners

Latest:

US Urology Partners Names Healthcare Visionary Raoul S. Concepcion, MD, as Chief Science Officer

Concepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.


Brian Myre, MD

Latest:

Letter: Declassifying Gleason 6 as a cancer would do more harm than good

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.


Sean P. Collins, MD, PhD

Latest:

Multidisciplinary Care in Prostate Cancer

In the second article of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, discuss multidisciplinary care practices in prostate cancer, with a focus on communication across specialties.


Jason M. Broderick and Cheryl Guttman Krader, BS, Pharm

Latest:

PINNACLE trial aims to confirm pilot success with BPH drug-coated balloon catheter

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.



Sandip M. Prasad, MD, MPhil

Latest:

EP. 2B: Radical Nephroureterectomy vs Kidney-sparing Approaches for Patients with LG UTUC

In this companion article, Sandip M. Prasad, MD, MPhil, from the Morristown Medical Center in New Jersey discusses the historic use of radical nephroureterectomy and provides an overview of his clinical experience using kidney-sparing approaches for LG UTUC.


Scott Sellinger, MD, FACS

Latest:

Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.


Rebekah Bernard, MD

Latest:

A physician’s advice for defusing patient anger

Rebekah Bernard, MD, provides tips for improving interactions with patients who are angry.


Max Schloemann

Latest:

Urology Practice advice: prioritize billing and coding oversight

When a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.


Sujith Puskoor, DO

Latest:

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.


Andrew G. McIntosh, MD

Latest:

Radical nephrectomy before or after systemic therapy for mRCC

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.


Brandon Daniell

Latest:

How text messaging can be a valuable tool for your practice

Here are seven ways texting can improve healthcare revenue and decrease costs.


Bryan S. Sack, MD

Latest:

Integrating video visits into urologic training

"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.


Kyle Doherty

Latest:

FDA grants priority review to enzalutamide for nonmetastatic HSPC

The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.


Cynthia Sener, MBA

Latest:

Managing your online reputation in health care

While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.


Will Pizii

Latest:

Neoadjuvant chemoimmunotherapy combo shows promise in UTUC

The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.


University Hospitals

Latest:

Register Today! UH Urology Institute’s Fall Symposiums

University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.


Allina Health Cancer Institute

Latest:

Allina Health Cancer Institute 2022 Symposium reimagines cancer care

The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.


Richard G. Harris, MD, FACS

Latest:

Letter: Declassifying Gleason 6 as a cancer would do more harm than good

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.


Jamie Cesanek

Latest:

Abiraterone-based triplet boosts survival in de novo mCSPC

Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.


Jennifer A. Linehan, MD

Latest:

Why favor high intensity focused ultrasound for treating localized prostate cancer?

"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.


Michael Parisi

Latest:

Smaller medical practices increasingly targeted for cyber attacks

Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.

© 2023 MJH Life Sciences

All rights reserved.